Category - Features

Features

Novamind building infrastructure for regulated psychedelic industry

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

October 20, 2020

Features

Lantern Pharma applying AI to discover and develop cancer therapeutics

Lantern Pharma (NASDAQ:LTRN) is using its RADR AI platform to identify abandoned drug candidates and develop new drugs that may prove effective in treating certain cancers.

October 13, 2020

Features

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Features

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

September 22, 2020

Features

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Features

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary uro-oncology...

September 8, 2020

Features

IDbyDNA commercializing Explify platform for comprehensive pathogen detection and surveillance

Closely-held clinical metagenomics company, IDbyDNA, is commercializing its Explify platform with the goal of replacing traditional pathogen detection with a data-driven approach. “Our vision is to deploy our...

September 1, 2020

Features

Axolotl Biosciences developing bioink for 3D neural tissue bioprinting

Closely-held Axolotl Biosciences is developing a bioink specifically formulated for the bioprinting of neural tissue, for biotechnology and pharmaceutical companies to use for research and development purposes. “Last...

August 25, 2020

Features

Chiasma readies U.S. launch of first oral somatostatin analog for acromegaly

On the heels of an FDA approval, Chiasma (NASDAQ:CHMA) is preparing for the U.S. launch of MYCAPSSA, the first orally administered somatostatin analog for the long-term maintenance treatment of acromegaly in patients...

August 18, 2020

Category - Features

Novamind building infrastructure for regulated psychedelic industry

Lantern Pharma applying AI to discover and develop cancer therapeutics

Monopar Therapeutics readies two key clinical trials in fourth quarter

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Trendlines’ PregnanTech developing Lioness device to prevent preterm birth

BioCardia developing autologous and allogenic cardiovascular cell therapies

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

IDbyDNA commercializing Explify platform for comprehensive pathogen detection and surveillance

Axolotl Biosciences developing bioink for 3D neural tissue bioprinting

Chiasma readies U.S. launch of first oral somatostatin analog for acromegaly

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter